Johanna F Dekkers, Maria Alieva, Astrid Cleven, Farid Keramati, Amber K L Wezenaar, Esmée J van Vliet, Jens Puschhof, Peter Brazda, Inez Johanna, Angelo D Meringa, Heggert G Rebel, Maj-Britt Buchholz, Mario Barrera Román, Amber L Zeeman, Sam de Blank, Domenico Fasci, Maarten H Geurts, Annelisa M Cornel, Else Driehuis, Rosemary Millen, Trudy Straetemans, Mara J T Nicolasen, Tineke Aarts-Riemens, Hendrikus C R Ariese, Hannah R Johnson, Ravian L van Ineveld, Froso Karaiskaki, Oded Kopper, Yotam E Bar-Ephraim, Kai Kretzschmar, Alexander M M Eggermont, Stefan Nierkens, Ellen J Wehrens, Henk G Stunnenberg, Hans Clevers, Jürgen Kuball, Zsolt Sebestyen, Anne C Rios
Extending the success of cellular immunotherapies against blood cancers to the realm of solid tumors will require improved in vitro models that reveal therapeutic modes of action at the molecular level. Here we describe a system, called BEHAV3D, developed to study the dynamic interactions of immune cells and patient cancer organoids by means of imaging and transcriptomics. We apply BEHAV3D to live-track >150,000 engineered T cells cultured with patient-derived, solid-tumor organoids, identifying a 'super engager' behavioral cluster comprising T cells with potent serial killing capacity...
January 2023: Nature Biotechnology